UNSPSC 51361906: Benzobarbital

This classification denotes a barbiturate with the molecular formula C19H16N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YNJ78BD0AH, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 1-benzoyl-5-ethyl-5-phenyl- (9ci) but generally known as benzobarbital, which bears US NIH Compound Identifier 12938. European Medicines Agency schedules Benzobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05754MIG.

UNSPSC 51361906 Benzobarbital is a Commodity code that nominally addresses a specific barbiturate pharmaceutical; however, recent state and local procurement activity under this code shows minimal direct relevance to the code's narrow product scope. The three most recent opportunities posted under or near this code address broader pharmaceutical and public-health procurement—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with OTC products—rather than benzobarbital specifically. This pattern suggests either tagging misalignment or that the code is used as a catch-all placeholder for pharmaceutical commodities that do not map neatly to narrower product-specific codes. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states and local governments (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work being solicited spans public-health emergency response, state pharmacy benefit management, and bulk pharmaceutical supply to government healthcare facilities.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative structure extending eligibility to Oregon and other participating jurisdictions. Recent opportunities include Seminole County's competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's Request for Information (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription program capabilities; and MMCAP's Request for Proposal (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The MMCAP opportunity emphasizes cGMP and Drug Supply Chain Security Act compliance, $5 million commercial general liability insurance, and price competitiveness weighted at 75 percent of evaluation. No set-aside designations are evident in the posted materials. Activity under this code is sparse and does not reflect sustained or concentrated procurement demand for benzobarbital itself.